Objective: The aim of this study was to explore the clinical characteristics of renal metastatic cancer, the methods for its detection by radioiodine ( 
I treatment in fourteen patients with renal metastases from differentiated thyroid carcinoma (DTC). Subjects and methods: DTC patients (n = 2,955) that received treatment with 131 I were retrospectively analyzed. Scans ( (1) . The overall prognosis for DTC patients is one of the best among all types of cancer, with a 10-year survival rate over 85-90%, but its incidence is gradually increasing in different parts of the world (2,3). Although DTC is generally characterized by an indolent course with low mortality, patients with distant metastases have strong prognosis of mortality, and more than 50% of these DTC patients die from distant metastatic disease during follow-up (4). Distant metastases derived from DTC occur in 5-23% of patients at presentation and during follow-up (5,6).
The major sites of distant metastases from DTC are the lungs and bones, while minor sites include the brain, liver, skin, and muscle. In contrast, renal metastases from DTC are extremely rare. Ahmed 
SUBJECTS AND METHODS

Evaluation of efficacy
The therapeutic effects of 131 I therapy for renal metastases from DTC were evaluated based on changes in serum Tg levels and alterations in the anatomical imaging of renal metastatic lesions. Serum Tg levels were measured with the Immulite chemiluminescent immunoassay system (Diagnostic Products Corporation, Los Angeles, CA, USA). Serum TSH and anti-Tg antibody (TgAb) levels were also measured. The evaluation of anatomical images was performed based on methods established by RECIST 1.1. The responses defined by RECIST 1.1 are as follows: complete response (CR): disappearance of all target lesions, any pathological lesions (target or non-target) must have a reduction in short axis to < 10 mm; partial response (PR): at least a 30% decrease in the diameters of target lesions; progressive disease (PD): at least a 20% increase in the diameters of target lesions, combined with an absolute increase of at least 5 mm in the sum of diameters (in addition, appearance of one or more new lesions was also considered progression); stable disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increases to qualify for PD.
Statistical analysis
SPSS17.0 was used for statistical analysis. Tg changes were estimated by the Wilcoxon signed rank test. A p value < 0.05 was considered a statistically significant difference.
RESULTS
Demographic features of the patients
Fourteen patients were diagnosed with renal metastases from DTC with multimodality imaging, with an incidence of 0.47% (14/2955). The characteristics of these 14 DTC patients are summarized in table 1. Their ages ranged from 17 to 74 years, with a mean of 43 years.
Seven subjects were over 45 years of age, and seven were less than 45 years. Eight subjects were males and six were females (male-to-female ratio of 1.3:1). The distribution of DTC pathological types included nine cases of papillary thyroid cancer and five cases of follicular thyroid cancer. Of the 14 cases, only one (case 14) had a single renal metastasis, whereas 13 cases presented combined metastases to other organs: 11 patients had lung metastases, seven had bone metastases, three had mediastinal metastases, and there was one case each of metastasis to the brain, muscle, liver, and parapharyngeal region. Renal metastases were asymptomatic in nine patients, but found on imaging follow-up studies. Three patients had symptoms of lower back pain, and two had hematuria.
DETECTION OF RENAL METASTASES FROM DTC Discovery of functional renal metastases
Renal metastases from DTC that were detected with multimodality imaging are shown in figure 1. In the detection of renal metastases from DTC after I uptake) in the abdomen of 11 DTC patients, suggesting distant metastases from DTC, of which a total of 10 patients with 13 lesions were located in the kidneys after 131 I-SPECT/CT. Four cases with four lesions were found in the left kidneys, four cases with four lesions were found in the right kidneys, and two cases with five lesions were bilateral; among them, one case (case 7) with three lesions was found bilateral in the kidneys, one lesion in the left kidney and two lesions in the right kidney. Of those 10 patients with 13 renal metastatic lesions revealed by 131 I-SPECT/CT, all patients were SPECT-positive; but only three patients with five lesions (cases 6, 8, and 10) were CT-positive, with the remaining eight lesions of seven DTC patients (cases 2, 3, 4, 7, 9, 11, and 14) presenting equivocal or negative CT, suggesting early or small renal metastases. In these seven patients, three (cases 2, 4, and 7) were synchronous with MRI (Figure 2 ), three (cases 9, 12, and 14) with US, and one case (case 3) with enhanced CT. Among the remaining eight 131 I-uptake foci, one renal metastatic lesion in a DTC patient with lower back pain (case 1) was shown by 131 I-WBS combined with US, and others were excluded and identified as five intestinal uptake sites, one liver metastasis, and one erector spinae by 131 I-SPECT/CT. 
Diagnosis of renal metastases from DTC
Among 14 DTC patients with renal metastases, ten cases (71.43%) were diagnosed based on pathological results (cases 1, 2, 5, 6, 8, 9, 10, 11, 12, and 13) and the remaining four cases (28.57%) with renal metastases also should be considered by clinical follow-up because lesions were considered too small for a fine-needle aspiration biopsy. Moreover, . Serum Tg levels in 81.82 % (9/11) of the patients showed a gradual decline, while 18.18% (2/11) of the patients showed a significant elevation. In one patient (case 14), serum Tg level was normal and stabilized at about 2.56 and 9.3 ng/mL; however, TgAbs were obviously high and changed from 327 to 92 u/mL after several 131 I treatments (Table 2) .
Changes in serum Tg
Anatomical imaging changes after
I therapy
Of the 11 cases with renal metastases, only one patient presented PR and eight patients exhibited SD; these findings suggest that the disease remains stable. The renal metastases progressed in two patients showing PD. No patient reached CR (Table 2) . metastasis to the kidneys is quite rare; a retrospective review of the literature revealed only 26 case reports of renal metastases arising from DTC. Of the 26 cases of renal metastasis associated with DTC, full-text studies of three patients were not found using the PubMed and EMBASE databases; the other 23 patients are reviewed in table 3 (7, . We previously reported one case of renal metastases from DTC, a 29-year-old man with concomitant metastases to the erector spinae and lungs (case 7) (19) . Most subjects were females over 45 years of age; nine cases were FTC, 10 cases PTC, three cases a follicular variant of PTC, and one case of Hurthle cell thyroid cancer. However, because of its limited expression and rarity, renal metastasis from DTC has only been occasionally reported, mainly as case reports or a small case series. Here, a relatively large number of DTC cases from renal metastasis were described in this study. The overall prevalence of renal metastasis from DTC was about 0.47% (14 of 2,955). Similar to our patients, most of the previously reported patients had advanced DTC with metastases to other organs when renal metastases were found. In our study, a 31-yearold female with a single left renal metastasis from DTC was the only case detected by I-SPECT/CT has emerged in this setting as a useful tool for accurately locating sites of pathological uptake and identifying physiological mimics of disease, thus providing a more accurate staging of prognostic information for risk stratification which, in its turn, tailors management and follow-up regimens (37) .
131
I-SPECT/CT for anatomic localization of renal metastases has been reported in past reviews (19, 20) . In our cases, 10 DTC patients with renal metastases were detected by 
DISCUSSION
Differentiated thyroid cancer (DTC) has been reported to present initially distant metastases in about 4% of cases. During follow-up, distant metastases develop in 2-34% of cases (12) . The presence of distant metastases reflects advanced clinical presentation, associated with higher mortality rate, especially in elderly patients (13) . However,
131
I-WBS combined with elevated serum Tg can contribute to the early detection of distant metastases (at a time when other radiological studies are negative), and the disease is potentially curable by means of 131 I therapy (14, 15) . The major sites of distant metastases from DTC are the lungs and bones, while other sites infrequently involved include the brain, liver, skin, pleura, and muscle. Metastasis to the kidneys is not an uncommon incidental finding at autopsy; 4.6-7.6% of patients have metastases in the kidneys, with frequencies of bilaterality and multiplicity being as high as 71-81% (16) . Metastases to the kidney from papillary and follicular thyroid cancer are found in 2.8-3.8% and 6-20% of cases, respectively (17) . However, the clinical detection of DTC I non-avidity and FDG uptake suggest their high grade (38) .
In clinical settings, most conventional imaging such as US, enhanced CT, and MRI are performed for the evaluation of symptoms, disease staging, or the evaluation of treatment response. Therefore, renal metastases from DTC cannot be considered for these conventional F-FDG-FET, but negative or equivocal in CT scans in the follow-up of DTC. These other modalities, including US, enhanced CT, and MRI, are especially useful tools to detect small (< 1 cm) or cryptic renal lesions unseen on CT scans. Of the 14 patients here, four were further identified by MRI scan, four by US, one by enhanced CT, and one by biopsy. Therefore, multimodality imaging is essential to accurately assess the extent of renal metastases from DTC to guide treatment, prevent tumor progression, and improve survival. Due to the rare occurrence of renal metastases from DTC, the best management for this condition is unclear. Since most cases are associated with metastases at other sites, surgical excision, with its risks and limited efficacy, is not a practical solution. Although external beam radiotherapy can provide local tumor control in a high percentage of cases, its efficacy is transient and dose-dependent. To obtain a longer lasting efficacy, a high dose of irradiation may be required and adverse effects must be considered. In addition, it is usually applied to treat a single metastasis and is unsuitable for the treatment of multiple metastases.
Sorafenib is a multikinase inhibitor that targets several molecular signals involved in the pathogenesis of DTC, and that has been used in the treatment of advanced or metastatic 131 I-refractory DTC (41) . However, it has only been reported as an anti-cancer drug for DTC with distant metastases, but not avid 131 I lung metastases, in recent years. Therefore, these treatments have not been applied in this group of patients. Currently, 131 I therapy is the treatment of choice for most DTC patients with distant metastases after thyroidectomy. If renal metastases from DTC have excellent 131 I uptake, they can be differentiated from other malignant neoplasms based on this feature, and be treated with 131 I. However, there are no data showing the efficacy of 131 I for the treatment of renal metastases from DTC due to their rarity. Here, the therapeutic effects of 131 I therapy on renal metastases from DTC were evaluated based on changes in serum Tg and alterations in anatomical imaging of metastatic renal lesions. In our study, among the 14 DTC patents with renal metastases, 11 patients showed avidity for 131 I. Serum Tg is a highly sensitive and specific marker of DTC metastasis and recurrence, which also reflects tumor burden. Serum Tg is usually significantly elevated in DTC patients with distant metastases. Thus, the pronounced reduction in Tg (at roughly the same TSH level) indicates that 131 I therapy can eliminate some tumor cells after multiple treatments (4). In our study, serum Tg levels in 81.82% (9/11) patients showed a gradual decline and 18.18% (2/11) patients showed a significant elevation, suggesting that 131 I is partly effective for the treatment of DTC patients with renal metastases. Because the detection of Tg may be disturbed by TgAbs, we measured serum levels of Tg and TgAbs simultaneously in all patients. In only one patient in this study, serum TgAb levels increased to a certain extent (> 100 ng/mL) but Tg levels were normal and stabilized at about 2.56 and 9.3 ng/mL. After 131 I therapy, serum levels of TgAbs decreased markedly. After 131 I therapy, MRI examinations revealed statistically significant shrinking of metastatic renal lesions in only one patient. This improvement may be due to small lesions or those that were at an early stage. The anatomical imaging of renal metastases with excellent avidity for 131 I showed insignificant changes in eight patients (72.73%), indicating that those lesions were stable. Though renal metastatic foci accumulated 131 I, US still showed PD in a patient, suggesting renal metastasis in this DTC patient may exhibit dedifferentiation (42) . Renal metastatic foci in the remaining three patients gradually increased without 131 I uptake after 131 I treatment. Therefore, 131 I treatment is ineffective for patients with a relatively poor prognosis.
